by Nikol Snoeren, Sander R. van Hooff, Rene Adam, Richard van Hillegersberg, Emile E. Voest, Catherine Guettier, Paul J. van Diest, Maarten W. Nijkamp, Mariel O. Brok, Dik van Leenen, Marian J. A. Groot Koerkamp, Frank C. P. Holstege, Inne H. M. Borel Rinkes
Background and Objectives
This study was designed to identify and validate gene signatures that can predict disease free survival (DFS) in patients undergoing a radical resection for their colorectal liver metastases (CRLM). Methods
Tumor gene expression profiles were collected from 119 patients undergoing surgery for their CRLM in the Paul Brousse Hospital (France) and the University Medical Center Utrecht (The Netherlands). Patients were divided into high and low risk groups. A randomly selected training set was used to find predictive gene signatures. The ability of these gene signatures to predict DFS was tested in an independent validation set comprising the remaining patients. Furthermore, 5 known clinical risk scores were tested in our complete patient cohort. Result
No gene signature was found that significantly predicted DFS in the validation set. In contrast, three out of five clinical risk scores were able to predict DFS in our patient cohort. Conclusions
No gene signature was found that could predict DFS in patients undergoing CRLM resection. Three out of five clinical risk scores were able to predict DFS in our patient cohort. These results emphasize the need for validating risk scores in independent patient groups and suggest improved designs for future studies.